2 Alzheimer's disease (AD), also known as Senile Dementia of the Alzheimer Type (SDAT) or simply Alzheimer s is the most common form of dementia. This incurable, degenerative, terminal disease was first described by a German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him. Alzheimer's disease (AD) is a slowly progressive disease of the brain that is characterized by impairment of memory and eventually by disturbances in reasoning, planning, language, and perception. Many scientists believe that Alzheimer's disease results from an increase in the production or accumulation of a specific protein (beta-amyloid protein) in the brain that leads to nerve cell death.
3 Generally, it is diagnosed in people over 65 years of age, although the less-prevalent early onset of Alzheimer s can occur much earlier. In 2006, there were 26.6 million sufferers worldwide. Alzheimer s is predicted to affect 1 in 85 people globally by 2050.
5 1) Early Stage This is considered as a mild/early stage and the duration period is 2-4 years. Frequent recent memory loss, particularly of recent conversations and events. Repeated questions, some problems expressing and understanding language. Writing and using objects become difficult and depression and apathy can occur. Drastic personality changes may accompany functional decline. Need reminders for daily activities and difficulties with sequencing impact driving early in this stage.
6 2) Second stage This is considered as a middle/moderate stage and the duration is 2-10 years. Can no longer cover up problems. Pervasive and persistent memory loss impacts life across settings. Rambling speech, unusual reasoning, confusion about current events, time, and place. Potential to become lost in familiar settings, sleep disturbances, and mood or behavioral symptoms accelerate. Nearly 80% of patients exhibit emotional and behavioral problems which are aggravated by stress and change. Slowness, rigidity, tremors, and gait problems impact mobility and coordination. Need structure, reminders, and assistance with activities of daily living.
7 3) Moderate stage Increased memory loss and confusion. Problems recognizing family and friends. Inability to learn new things. Difficulty carrying out tasks that involve multiple steps (such as getting dressed). Problems coping with new situations. Delusions and paranoia. Impulsive behavior. In moderate AD, damage occurs in areas of the brain that control language, reasoning, sensory processing, and conscious thought
8 4) Last stage This is considered as the severe stage and the duration is 1-3 years. Confused about past and present. Loss of recognition of familiar people and places Generally incapacitated with severe to total loss of verbal skills. Unable to care for self. Falls possible and immobility likely. Problems with swallowing, incontinence, and illness. Extreme problems with mood, behavioral problems, hallucinations, and delirium. Patients need total support and care, and often die from infections or pneumonia
9 Alzheimer's disease is usually diagnosed clinically from the patient history, collateral history from relatives, and clinical observations, based on the presence of characteristic neurological and neuropsychological features and the absence of alternative conditions. Advanced medical imaging with computed tomography (CT) or magnetic resonance imaging (MRI), and with single photon emission computer tomography (SPECT) or positron emission tomography (PET) can be used to help exclude other cerebral pathology or subtypes of dementia. The diagnosis can be confirmed with very high accuracy post-mortem when brain material is available and can be examined histologically.
10 . PET scan of the brain of a person with AD showing a loss of function in the temporal lobe.
11 Neuropsychological tests such as the mini-mental state examination (MMSE) are widely used to evaluate the cognitive impairments needed for diagnosis. More comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease. Psychological tests for depression are employed, since depression can either be concurrent with AD, an early sign of cognitive impairment, or even the cause. When available as a diagnostic tool, SPECT and PET neuroimaging are used to confirm a diagnosis of Alzheimer's in conjunction with evaluations involving mental status examination. In a person already having dementia, SPECT appears to be superior in differentiating Alzheimer's disease from other possible causes, compared with the usual attempts employing mental testing and medical history analysis.
12 Scientists don t yet fully understand what causes AD, but it is clear that it develops because of a complex series of events that take place in the brain over a long period of time. It is likely that the causes include genetic, environmental, and lifestyle factors. Some drug therapies propose that AD is caused by reduced synthesis of the neurotransmitter acetylcholine. Other cholinergic effects have also been proposed, for example, initiation of large-scale aggregation of amyloid leading to generalized neuroinflammation. Alzheimer's disease is characterized by a build-up of proteins in the brain. Though this cannot be measured in a living person, extensive autopsy studies have revealed this phenomenon. The build-up manifests in two ways: Plaques deposits of the protein beta-amyloid that accumulate in the spaces between nerve cells Tangles deposits of the protein tau that accumulate inside of nerve cells
13 Microscopy image of a neurofibrillary tangle, conformed by hyperphosphorylated tau protein.
14 Alzheimer's disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This loss results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus. Both amyloid plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those afflicted by AD. Plaques are dense, mostly insoluble deposits of amyloid beta peptides and cellular material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of ageing, the brains of AD patients have a greater number of them in specific brain regions such as the temporal lobe.
15 Alzheimer's disease has been identified as a protein misfolding disease (proteopathy), caused by accumulation of abnormally folded A-beta and tau proteins in the brain. Plaques are made up of small peptides, amino acids in length, called beta-amyloid (also written as A-beta or Aβ). Beta-amyloid is a fragment from a larger protein called amyloid precursor protein (APP), a transmembrane protein that penetrates through the neuron's membrane. APP is critical to neuron growth, survival and post-injury repair. In Alzheimer's disease, an unknown process causes APP to be divided into smaller fragments by enzymes through proteolysis. One of these fragments gives rise to fibrils of beta-amyloid, which form clumps that deposit outside neurons in dense formations known as senile plaques. AD is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the axon and back. A protein called tau stabilizes the microtubules when phosphorylated, and is therefore called a microtubule-associated protein. In AD, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron's transport system.
16 Enzymes act on the APP (amyloid precursor protein) and cut it into fragments. The beta amyloid fragment is crucial in the formation of senile plaques in AD.
17 Exactly how disturbances of production and aggregation of the beta amyloid peptide gives rise to the pathology of AD is not known. The amyloid hypothesis traditionally points to the accumulation of beta amyloid peptides as the central event triggering neuron degeneration. Accumulation of aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis, induces programmed cell death (apoptosis). It is also known that Aβ selectively builds up in the mitochondria in the cells of Alzheimer's-affected brains, and it also inhibits certain enzyme functions and the utilization of glucose by neurons. Various inflammatory processes and cytokines may also have a role in the pathology of Alzheimer's disease. Inflammation is a general marker of tissue damage in any disease, and may be either secondary to tissue damage in AD or a marker of an immunological response. Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain derived neurotrophic factor (BDNF) have been described in AD
19 Apolipoprotein E (APOE) found on chromosome 19 appears to be a predisposing genetic risk factor for the late on-set of AD the most typical AD. APOE helps carry cholesterol in the bloodstream. APOE comes in several different forms, or alleles. Three forms APOE ε2, APOE ε3, and APOE ε4 occur most frequently.
21 Aricept Used to delay or slow the symptoms of AD Donepezil Loses its effect over time Used for mild, moderate and severe AD Does not prevent or cure AD Celexa Citalopram Used to reduce depression and anxiety May take 4 to 6 weeks to work Sometimes used to help people get to sleep Depakote Used to treat severe aggression Sodium Valproate Also used to treat depression and anxiety Exelon Used to delay or slow the symptoms of AD Rivastigmine Loses its effect over time Used for mild to moderate AD Can get in pill form or as a skin patch Does not prevent or cure AD
22 Namenda Used to delay or slow the symptoms of AD Memantine Loses its effect over time Used for moderate to severe AD Sometimes given with Aricept, Exelon Does not prevent or cure AD Razadyne Used to prevent or slow the symptoms of AD Galantamine Loses its effect over time Used for mild to moderate AD Can get in pill form or as a skin patch Does not prevent or cure AD Zoloft Used to reduce depression and anxiety Sertraline May take 4 to 6 weeks to work Sometimes used to help people get to sleep Trileptal Used to treat severe aggression Oxcarbazepine Also used to treat depression and anxiety Tegretol Used to treat severe aggression Carbamazepine Also used to treat depression and anxiety Remeron Used to reduce depression and anxiety Mirtazepine May take 4 to 6 weeks to work Sometimes used to help people get to sleep
23 Although there is currently no way to cure Alzheimer's disease or stop its progression, researchers are making encouraging advances in Alzheimer's treatment, including medications and non-drug approaches to improve symptom management. Mild/Moderate AD: Cholinesterase inhibitors increase the levels of acetylcholine in the brain, which plays a key role in memory and learning. This kind of drug postpones the worsening of symptoms for 6 to 12 months in about half of the people who take it. Cholinesterase inhibitors most commonly prescribed for mild to moderate Alzheimer's disease include Aricept (donezepil HCL), Exelon (rivastigmine), and Razadyne (galantamine).
24 Moderate/Severe AD: Namenda (memantine) regulates glutamate in the brain, which plays a key role in processing information. This drug is used to treat moderate to severe Alzheimer's disease and may delay the worsening of symptoms in some people. It may allow patients to maintain certain daily functions a little longer than they would without the medication.
25 Razadyne Razadyne (galantamine HBr) is FDA-approved for mild and moderate stages of the disease. Razadyne is a cholinesterase inhibitor that prevents the breakdown of acetylcholine in the brain. Acetylcholine plays a key role in memory and learning; higher levels in the brain help nerve cells communicate more efficiently. Razadyne also stimulates nicotinic receptors to release more acetylcholine in the brain.
26 Razadyne delays the worsening of Alzheimer's symptoms for 6 to 12 months in about half of the people who take it. Razadyne is available in tablet and capsule form, and is commonly started at 4 mg twice a day. If it's well tolerated after 4 weeks, the dosage may be increased to 8 mg twice a day. Razadyne also comes in an extended release, once-a-day tablet. Razadyne is available in generic form (galantamine HBr).
27 Exelon (Rivastigmine) Exelon is FDA approved for mild and moderate stages of the disease; it is also approved for the treatment of mild to moderate dementia due to Parkinson's disease. Exelon is available as a capsule, liquid, and patch.
28 Exelon is a cholinesterase inhibitor that prevents the breakdown of acetylcholine and butyrylcholine in the brain by blocking the activity of two different enzymes. Acetylcholine and butyrylcholine play a key role in memory and learning. When given orally, bioavailability is about 40% in the 3 mg dose. The compound can cross the blood-brain barrier.
29 Aricept (Donepizel) One of the most widely used drugs to treat the symptoms of Alzheimer's disease. Aricept is FDA-approved for mild, moderate, and severe stages of the disease.
30 Aricept is available in tablet form or an orally disintegrating tablet form, and is commonly started at 5 mg a day. Can cross the blood-brain barrier.
31 Namenda (Memantine) Namenda is an N-methyl D-aspartate (NMDA) antagonist that regulates the activity of glutamate in the brain. Glutamate plays a key role in memory and learning, but excess glutamate can lead to the disruption of nerve cell communication or nerve cell death.
What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,
Concepts in the Evolution of and Treatment Approaches Arnold Bakker, Ph.D. Department of Psychiatry and Behavioral Sciences Johns Hopkins University School of Medicine Dementia Criteria for dementia: Memory
Alzheimer s Disease FACT SHEET Alzheimer s disease is an irreversible, progressive brain disease that slowly destroys memory and thinking skills, and eventually even the ability to carry out the simplest
DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of
Alzheimer s Disease 1818 Society World Bank December 4, 2015 Raya Elfadel Kheirbek, MD, MPH The global impact of dementia Around the world, there is 9.9 million new cases of dementia in 2015, one every
Overview of Alzheimer s Disease Today s Objectives Provide an overview of Alzheimer s disease and related dementias Where can individuals, families and professionals get help Services available What is
What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There
The Principles of Dementia Care S A M P LE NCFE Level 2 Certificate in The Principles of Dementia Care Part A 1 These learning resources and assessment questions have been approved and endorsed by ncfe
Inception, Total Recall, & The Brain: An Introduction to Neuroscience Part 2 Neal G. Simon, Ph.D. Professor Dept. of Biological Sciences http://www.youtube.com/watch?v=wfmlgeh dije Summary from September
Delirium & Dementia Nicholas J. Silvestri, MD Outline Delirium vs. Dementia Neural pathways relating to consciousness Encephalopathy Stupor Coma Dementia Delirium vs. Dementia Delirium Abrupt onset Lasts
Module 4: Introduction to ID and Dementia Matthew P. Janicki, Ph.D. email@example.com 1 Section Objectives Participants will be able to: Identify how dementia may appear different in adults with ID. Apply
Dementia and cognitive decline Expert Briefing Su Ray and Dr Susan Davidson Research Department Together, we can help everyone to love later life 01 Brain basics Normal ageing, cognitive impairment and
DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017. Introduction. Parkinson's disease (PD) has been considered largely as a motor disorder. It has been increasingly recognized that
What is dementia? What is dementia? What is dementia? Dementia is an umbrella term for a range of progressive conditions that affect the brain. There are over 200 subtypes of dementia, but the five most
The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,
The Psychopharmacology of Alzheimer s Disease Bruce Kaster, MD Instructor in Psychiatry Harvard Medical school Overview of Alzheimer s Disease Alzheimer s is a progressive degenerative disease Prevalence
Dementia Memory Evaluation Center Neurology Topics Overview of dementia Stages Medications Advanced planning What is Dementia? Dementia = significant global decline in cognitive function not due to medicine
Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor
Disorders of Aging and Cognition Chapter 18 Slides & Handouts by Karen Clay Rhines, Ph.D. Northampton Community College Comer, Abnormal Psychology, 8e Disorders of Aging and Cognition Dementia deterioration
Corporate Medical Policy Genetic Testing for Alzheimer s Disease File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_alzheimers_disease 8/2010 10/2017 10/2018 10/2017
A new, Talking local and About independent the Hard organization Stuff: Beyond memory loss March 5, 2016 Alzheimer s Overview Mary Ball President & CEO In partnership with Welcome! Mary Ball, President/CEO
Delirium, Dementia, and Amnestic Disorders Dr.Al-Azzam 1 Introduction Disorders in which a clinically significant deficit in cognition or memory exists The number of people with these disorders is growing
Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes
Dementia Jeanette Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine What is Dementia? Dementia is a general term referring to a decline in cognitive/mental functioning; this decline
Mental Health Counseling for mood, aging, and coping with life transitions and chronic illness. Silver Linings for Seniors Silver Linings for Seniors, Inc. offers on-site confidential Mental Health Counseling
PBO 930022142 NPO 049-191 What is Alzheimer s disease Alzheimer s disease is the most common form of dementia. This information sheet outlines the symptoms and cause of Alzheimer s disease and describes
2018 ALZHEIMER S DISEASE FACTS AND FIGURES Includes a Special Report on the Financial and Personal Benefits of Early Diagnosis About this report 2018 Alzheimer s Disease Facts and Figures is a statistical
P20.2. Characteristics of different types of dementia and challenges for the clinician, professor Danish Dementia Research Center Rigshospitalet, University of Copenhagen (Denmark) This project has received
Plasma Phospholipids Identify Antecedent Memory Impairment in Older Adults Madeline Haff, Bikem Sonmezler, & Rosie Chu So what exactly is Alzheimer s Disease? A progressive form of dementia that causes
In-Service Education workbook 3 second edition by Hartman Publishing, Inc. Alzheimer s Disease Dignity Diabetes Restraints and Restraint Alternatives Abuse and Neglect Death and Dying Managing Stress Perf
Shaping the Future of Dementia Care Cheryl Miller, Phoebe Ministries Staff Development Coordinator Objectives By the end of this session attendees will be able to: 1. List three modifiable risk factors
Alzheimer s disease Treatment options Treatment options Recent research has greatly improved our knowledge of Alzheimer s disease. Treatments for the disease are now available that may help to alleviate
alzheimers.org.uk What is dementia? This factsheet explains what dementia is, including the causes and symptoms, and how it is diagnosed and treated. It also looks at some of the different types of dementia.
Epilepsy in dementia Dr. Yotin Chinvarun M..D. Ph.D. CEP, PMK hospital Case 1 M 90 years old Had a history of tonic of both limbs (Lt > Rt) at the age of 88 years old, eye rolled up, no grunting, lasting
PBO 930022142 NPO 049-191 The progression of dementia Although everyone experiences dementia in their own individual way, it can be helpful to think of the progression of dementia as a series of stages.
Body control systems Nervous system Nervous system Quick Sends message directly to target organ Endocrine system Sends a hormone as a messenger to the target organ Slower acting Longer lasting response
9/12/11 Chapter 12 Nervous Tissue Overview of the nervous system Cells of the nervous system Electrophysiology of neurons Synapses Neural integration Subdivisions of the Nervous System 1 Subdivisions of
What parts of your brain are you using right now? Body control systems Quick Sends message directly to target organ Endocrine system Frontal lobe Parietal lobe Movement and conscious thought; Frontal speech
Brain and Behavior Lecture 13 Technology has improved our ability to know how the brain works. Case Study (Phineas Gage) Gage was a railroad construction foreman. An 1848 explosion forced a steel rod through
Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends
Dementia Skills for In-Home Care Providers Seniors Helping Seniors September 7 & 12, 2016 Amy Abrams, MSW/MPH Education & Outreach Manager Alzheimer s San Diego Objectives Familiarity with the most common
Roger E. Kelley, M.D. Professor and Chairman Department of Neurology Tulane University School of Medicine New Orleans, Louisiana FINANCIAL DISCLOSURE No potential conflict of interest to disclose. OBJECTIVES
Mayo Alzheimer s Disease Research Clinic Education Center 2016 Programs & Information BROCHURE TITLE FLUSH RIGHT for Persons & Families impacted by Mild Cognitive Impairment Alzheimer s Disease Dementia
Alzheimer s Disease Neurological Bases and Informed Behavioral Interventions Peter T. Keenan Clinical Neuropsychologist Marshfield Clinic Minocqua Center What is Neuropsychology? Science of the relationship
2013 Alzheimer s disease facts and figures Includes a Special Report on long-distance caregivers 1 in 3 seniors dies with Alzheimer s or another dementia. Out-of-pocket expenses for long-distance caregivers
Supporting people with dementia and their carers Information for the public Published: 1 November 2006 nice.org.uk About this information NICEclinicalguidelinesadvisetheNHSoncaringforpeoplewithspe cificconditionsordiseasesandthetreatmentstheyshouldreceive.
Understanding Alzheimer s Disease Lora, diagnosed in 2004, with her daughter, Jill. What Is Alzheimer s Disease? Alzheimer s disease is a neurologic disorder that affects the brain. It causes dementia.
Nutraceuticals & Lifestyle Changes That Can Halt The Progression Of Alzheimer s by Dr. Gregory Smith DIET: Studies of dietary influences on Alzheimer's disease do not yet provide clear evidence. Also the
Dear Students, Welcome to AP Psychology! We will begin our course of study focusing on the nervous system with a particular emphasis on how the brain and neurotransmitters influence our behaviors. In preparation
I read all the available books by other [people with] Alzheimer s disease but they never had quite the same problems as each other, or as me. I t s not like other diseases, where there is a standard set
Dementia, Depression, and Delirium 2.0 Contact Hours Presented by: CEU Professor 7 www.ceuprofessoronline.com Copyright 8 2008 The Magellan Group, LLC All Rights Reserved. Reproduction and distribution
DEMENTIA (Major Neurocognitive Disorder) SUSAN BEHNAWA, M.D. DIVISION OF GERIATRIC MEDICINE AND GERONTOLOGY UC IRVINE HEALTH SCHOOL OF MEDICINE Objectives Review the epidemiology and social impact of Dementia
Chronic Traumatic Encephalopathy Provider and Parent Essentials Concussion Global Cast July 30, 2014 John Lockhart, MD Seattle Children s Hospital Chronic Traumatic Encephaly (CTE) Working Definition Chronic
Introduction to Dementia Care Dementia Care Training Kit Updated February 4, 2011 Care and Compliance Group, Inc 800.321.1727 www.careandcompliance.com INTRODUCTION Fundamental Precepts of Good Dementia
Treatments for Alzheimer s Disease A Quick Guide for Patients and Caregivers By Kelsey F. Lee, PharmD candidate 2011 Preceptor: Demetra Antimisiaris, PharmD University of Louisvlle Dept. Family Medicine
Decline in Mental Capacity Elder Law: Issues, Answers and Opportunities ALI-ABA, February 23-24, 2006 Robert B. Fleming 1 FLEMING & CURTI, P.L.C. 330 N. Granada Ave. Tucson, Arizona 85701 www.elder-law.com
Bio11: The Nervous System The human brain The brain processes and acts on information Home of intelligence Uses more energy than any other part of the body Mysteries of human brain 4:37 http://www.youtube.com/watch?v=glxu80ge7vg
DEMENTIA 2017 Unforgettable, that s what you are... Recorded by Nat King Cole, 1951, lyrics by Irving Gordon William T. Wake, M.D., F.A.A.F.P. Kaiser Permanente Departments of Family Medicine and Geriatrics,
Alzheimer's Disease, Prevalence, and Caregiving Specific information in this year s Alzheimer s Disease Facts and Figures includes: Proposed guidelines for diagnosing Alzheimer s disease from the National
FRONTOTEMPORAL DEGENERATION: OVERVIEW, TRENDS AND DEVELOPMENTS Norman L. Foster, M.D. Director, Center for Alzheimer s Care, Imaging and Research Chief, Division of Cognitive Neurology, Department of Neurology
John D. Schaeffer, DO PMG Neurology Missoula, MT Alzheimer s Disease First described by Alois Alzheimer, a German neuropathologist, in 1907 Observed in a 51-year-old female patient with memory loss, disorientation,
The Nervous System Neuron Nucleus Cell body Dendrites they are part of the cell body of a neuron that collect chemical and electrical signals from other neurons at synapses and convert them into electrical
Mid North Coast Rural Palliative Care Project Link Nurse Education 2004 Palliative Approach to the Person with Advanced Dementia Anne Sneesby CNC - ACAT To care for the dying is a very human opportunity
What is frontotemporal dementia? Introduction Information in this introductory booklet is for anyone who wants to know more about frontotemporal dementia (FTD). This includes people living with FTD, their
Managing Challenging Behaviors Barbara J. Kocsis, MD Psychiatry Resident, HDSA Center of Excellence UC Davis School of Medicine & Lorin M. Scher, MD Attending Psychiatrist, HDSA Center of Excellence UC
Okami Study Guide: Chapter 2 1 Chapter Test 1. A cell that receives information and transmits it to other cells via an electrochemical process is called a(n) a. neuron b. hormone c. glia d. endorphin Answer:
Disclosure Speaker Bureaus Pfizer Forest Norvartis Grant Support Pan American Health Organization/WHO NIA HRSA How Common is Psychosis in Alzheimer s Disease? Review of 55 studies 41% of those with Alzheimer
PBO 930022142 NPO 049-191 Aricept, Exelon and Reminyl the new drugs for Alzheimer s disease Aricept, Exelon and Reminyl are not cures for Alzheimer s disease. However, they can temporarily slow down the
#CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,
Raj C. Shah, MD Associate Professor in Family Medicine Rush Alzheimer s Disease Center Rush University Medical Center Raj_C_Shah@rush.edu From Legal Practice to What s Next: The Boomer-Lawyer s Guide to
Dementia: The Role of Neuropsychology and Finding the Right Diagnosis Robert E. Cohen, PsyD Director - Department of Neuropsychology Orlando Health Memory Disorder Clinic OBJECTIVES: Discuss the role of
A Palliative Approach in Caring for the Person and Family Living with Dementia Anne Carr, GNP BC Anne Mahler, GCNS BC, ACHPN Created May 2017 Disclosures Anne Carr and Anne Mahler have no real or perceived
GALANTAMINE THERAPEUTICS Brands Razadyne Razadyne ER see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: acetylcholine multi-modal; enzyme inhibitor; receptor PAM (ACh-MM)